Reviewing TG Therapeutics (NASDAQ:TGTX) & Bioheart (OTCMKTS:USRM)

TG Therapeutics (NASDAQ:TGTX) and Bioheart (OTCMKTS:USRM) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, dividends, earnings, institutional ownership and analyst recommendations.

Institutional & Insider Ownership

58.6% of TG Therapeutics shares are held by institutional investors. 10.6% of TG Therapeutics shares are held by insiders. Comparatively, 16.7% of Bioheart shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings for TG Therapeutics and Bioheart, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	0	2	3	1	2.83
Bioheart	0	0	0	0	0.00

TG Therapeutics presently has a consensus target price of $50.00, suggesting a potential upside of 47.78%. Given TG Therapeutics’ stronger consensus rating and higher possible upside, research analysts plainly believe TG Therapeutics is more favorable than Bioheart.

Risk and Volatility

TG Therapeutics has a beta of 1.68, meaning that its stock price is 68% more volatile than the S&P 500. Comparatively, Bioheart has a beta of -1.01, meaning that its stock price is 201% less volatile than the S&P 500.

Valuation and Earnings

This table compares TG Therapeutics and Bioheart”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TG Therapeutics	$616.29 million	8.77	$447.18 million	$2.77	12.21
Bioheart	N/A	N/A	N/A	N/A	N/A

TG Therapeutics has higher revenue and earnings than Bioheart.

Profitability

This table compares TG Therapeutics and Bioheart’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	72.56%	101.12%	51.88%
Bioheart	N/A	N/A	N/A

Summary

TG Therapeutics beats Bioheart on 10 of the 11 factors compared between the two stocks.

About TG Therapeutics

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

About Bioheart

U.S. Stem Cell, Inc., a biotechnology company, engages in the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States. The company's lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia. Its pipeline products include MyoCell SDF-1, an autologous muscle-derived cellular therapy for enhancing cardiac function in chronic heart failure patients. The company is also developing MyoCath, a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure. In addition, it provides physician and patient based regenerative medicine/cell therapy training, cell collection, and cell storage services; and cell collection and treatment kits for humans and animals, as well as operates a cell therapy clinic to provide cellular treatments for patients afflicted with neurological, autoimmune, orthopedic, and degenerative diseases. The company also offers various courses for physicians and other health care professionals. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in October 2015. U.S. Stem Cell, Inc. was incorporated in 1999 and is headquartered in Sunrise, Florida.